The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors.

Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE

Publication: 2009- : London : BioMed Central
Original Publication: [Roma] : APSIT,

Biomarkers/*metabolism ; Drug-Related Side Effects and Adverse Reactions/*diagnosis ; Immune Checkpoint Inhibitors/*adverse effects ; Neoplasms/*drug therapy; Drug-Related Side Effects and Adverse Reactions/etiology ; Drug-Related Side Effects and Adverse Reactions/metabolism ; Humans ; Neoplasms/immunology ; Neoplasms/pathology

The enthusiasm for immune checkpoint inhibitors (ICIs), an efficient tumor treatment model different from traditional treatment, is based on their unprecedented antitumor effect, but the occurrence of immune-related adverse events (irAEs) is an obstacle to the prospect of ICI treatment. IrAEs are a discrete toxicity caused by the nonspecific activation of the immune system and can affect almost all tissues and organs. Currently, research on biomarkers mainly focuses on the gastrointestinal tract, endocrine system, skin and lung. Several potential hypotheses concentrate on the overactivation of the immune system, excessive release of inflammatory cytokines, elevated levels of pre-existing autoantibodies, and presence of common antigens between tumors and normal tissues. This review lists the current biomarkers that might predict irAEs and their possible mechanisms for both nonspecific and organ-specific biomarkers. However, the prediction of irAEs remains a major clinical challenge to screen and identify patients who are susceptible to irAEs and likely to benefit from ICIs.

Oncotarget. 2017 Dec 14;8(69):114268-114280. (PMID: 29371985)
Eur J Immunol. 2013 May;43(5):1274-85. (PMID: 23400950)
Oncologist. 2020 Apr;25(4):e679-e683. (PMID: 32297443)
Adv Exp Med Biol. 2003;520:1-7. (PMID: 12613569)
Front Oncol. 2017 Apr 03;7:56. (PMID: 28421161)
Blood. 2014 Jul 10;124(2):188-95. (PMID: 24876563)
N Engl J Med. 2009 Aug 27;361(9):888-98. (PMID: 19710487)
J Immunother Cancer. 2015 Sep 15;3:39. (PMID: 26380086)
Medicine (Baltimore). 2018 Jan;97(3):e9617. (PMID: 29504990)
Biomed Res Int. 2015;2015:731469. (PMID: 25893197)
JAMA Oncol. 2018 Feb 1;4(2):173-182. (PMID: 28973656)
PLoS Pathog. 2013 Mar;9(3):e1003215. (PMID: 23516361)
Biochim Biophys Acta. 2011 May;1813(5):878-88. (PMID: 21296109)
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11695-700. (PMID: 16864790)
J Clin Endocrinol Metab. 2007 Jun;92(6):2038-40. (PMID: 17554056)
J Clin Oncol. 2006 May 20;24(15):2283-9. (PMID: 16710025)
J Oncol Pract. 2018 Apr;14(4):247-249. (PMID: 29517954)
Lancet Oncol. 2019 Sep;20(9):1239-1251. (PMID: 31345627)
Semin Immunopathol. 2019 Mar;41(2):165-175. (PMID: 30276446)
Nat Rev Genet. 2016 Mar;17(3):160-74. (PMID: 26907721)
Sci Rep. 2017 Mar 06;7:43492. (PMID: 28262761)
Clin Exp Allergy. 2017 Nov;47(11):1417-1425. (PMID: 28865147)
J Immunother Cancer. 2018 Sep 18;6(1):90. (PMID: 30227886)
N Engl J Med. 2018 Nov 22;379(21):2040-2051. (PMID: 30280635)
Nat Rev Immunol. 2006 Jun;6(6):433-46. (PMID: 16724098)
Genes Dev. 1999 Jun 1;13(11):1382-97. (PMID: 10364156)
Best Pract Res Clin Endocrinol Metab. 2005 Mar;19(1):1-15. (PMID: 15826919)
Oncoimmunology. 2019 Feb 18;8(4):e1568812. (PMID: 30906663)
J Transl Med. 2013 Mar 22;11:75. (PMID: 23521917)
Int J Breast Cancer. 2015;2015:145647. (PMID: 26693355)
Curr Opin Oncol. 2016 Jul;28(4):269-77. (PMID: 27138570)
Brain. 2007 Apr;130(Pt 4):1089-104. (PMID: 17438020)
Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(2):95-101. (PMID: 28603207)
J Clin Oncol. 2018 Jun 10;36(17):1714-1768. (PMID: 29442540)
Cancer Med. 2016 Oct;5(10):2792-2799. (PMID: 27683208)
Eur J Cancer. 2017 Sep;82:56-65. (PMID: 28648699)
Thyroid. 2002 Aug;12(8):725-31. (PMID: 12225642)
Arthritis Res Ther. 2005;7(5):R1001-13. (PMID: 16207316)
PLoS One. 2014 Feb 03;9(2):e87705. (PMID: 24498358)
N Engl J Med. 2012 Jun 28;366(26):2443-54. (PMID: 22658127)
N Engl J Med. 2015 Jan 22;372(4):320-30. (PMID: 25399552)
J Immunol. 2010 Mar 1;184(5):2646-54. (PMID: 20100934)
J Interferon Cytokine Res. 2011 Oct;31(10):695-703. (PMID: 21942420)
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22246-22251. (PMID: 31611368)
Eur J Cancer. 2016 Feb;54:139-148. (PMID: 26765102)
Blood. 2006 Jun 15;107(12):4807-16. (PMID: 16484589)
N Engl J Med. 2019 Mar 21;380(12):1116-1127. (PMID: 30779529)
J Immunother. 2012 Feb-Mar;35(2):169-78. (PMID: 22306905)
Endocr Rev. 2007 Aug;28(5):492-520. (PMID: 17475924)
Cancer Immunol Immunother. 2019 Jan;68(1):97-107. (PMID: 30311027)
J Transl Med. 2018 Apr 11;16(1):94. (PMID: 29642948)
Immunity. 1999 Aug;11(2):141-51. (PMID: 10485649)
Nat Med. 2003 Dec;9(12):1477-83. (PMID: 14595408)
Nat Rev Clin Oncol. 2020 Aug;17(8):504-515. (PMID: 32246128)
J Cancer Res Clin Oncol. 2019 Oct;145(10):2625-2631. (PMID: 31492984)
J Mol Endocrinol. 2013 Dec 19;52(1):R67-77. (PMID: 24049068)
Eur J Immunol. 2015 Mar;45(3):922-31. (PMID: 25487261)
Eur J Intern Med. 2018 Jan;47:6-13. (PMID: 28826822)
Nat Rev Drug Discov. 2016 Apr;15(4):235-47. (PMID: 26965203)
Ann Oncol. 2017 Jun 1;28(6):1368-1379. (PMID: 28368458)
Cancer Treat Rev. 2018 Feb;63:40-47. (PMID: 29207310)
Cancer. 2013 May 1;119(9):1675-82. (PMID: 23400564)
Blood. 2006 Jul 15;108(2):432-40. (PMID: 16543475)
Cancer Immun. 2010 Nov 24;10:11. (PMID: 21090563)
Nat Commun. 2016 Feb 02;7:10391. (PMID: 26837003)
J Exp Med. 1999 Nov 15;190(10):1367-70. (PMID: 10562311)
Carcinogenesis. 2009 Jul;30(7):1073-81. (PMID: 19468060)
Pituitary. 2016 Feb;19(1):82-92. (PMID: 26186958)
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. (PMID: 30242316)
Lancet Oncol. 2019 Aug;20(8):1083-1097. (PMID: 31221619)
JAMA Neurol. 2016 Aug 1;73(8):928-33. (PMID: 27271951)
BMC Med. 2015 Sep 04;13:211. (PMID: 26337719)
PLoS One. 2015 Dec 30;10(12):e0143080. (PMID: 26717416)
J Immunol. 2008 Apr 1;180(7):5130-40. (PMID: 18354239)
Sci Transl Med. 2014 Sep 17;6(254):254ra128. (PMID: 25232180)
JAMA Oncol. 2019 Jul 1;5(7):1043-1047. (PMID: 31021392)
Allergy Asthma Immunol Res. 2017 Jul;9(4):360-367. (PMID: 28497923)
Ann Transl Med. 2016 Jul;4(14):261. (PMID: 27563648)
Front Pharmacol. 2017 Feb 08;8:49. (PMID: 28228726)
Curr Opin Immunol. 2006 Apr;18(2):206-13. (PMID: 16464564)
Surg Today. 2017 Apr;47(4):483-489. (PMID: 27549777)
Jpn J Clin Oncol. 2019 May 1;49(5):431-437. (PMID: 30753621)
Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12204-9. (PMID: 20566854)
J Exp Med. 1999 Nov 15;190(10):1375-82. (PMID: 10562313)
Hum Vaccin Immunother. 2018;14(9):2178-2182. (PMID: 29494275)
J Biol Chem. 2000 Oct 27;275(43):33365-72. (PMID: 10931853)
JAMA Oncol. 2019 Mar 1;5(3):376-383. (PMID: 30589930)
J Dermatol Sci. 2017 Nov;88(2):225-231. (PMID: 28736218)
J Immunol. 2003 Jun 15;170(12):6320-8. (PMID: 12794165)
J Travel Med. 2009 May-Jun;16(3):149-60. (PMID: 19538575)
Nat Immunol. 2015 Jan;16(1):45-56. (PMID: 25521684)
Lancet Oncol. 2010 Feb;11(2):155-64. (PMID: 20004617)
Arthritis Rheum. 2008 Aug;58(8):2257-67. (PMID: 18668547)
Clin Genitourin Cancer. 2018 Dec;16(6):e1151-e1158. (PMID: 30213543)
J Biol Chem. 2011 Oct 28;286(43):37446-57. (PMID: 21873424)
N Engl J Med. 2018 Jan 11;378(2):158-168. (PMID: 29320654)
Thorac Cancer. 2020 Apr;11(4):835-839. (PMID: 32043828)
Endocrinology. 1992 Mar;130(3):1753-5. (PMID: 1311248)
N Engl J Med. 2017 Oct 5;377(14):1345-1356. (PMID: 28889792)
J Clin Endocrinol Metab. 2017 Aug 1;102(8):2770-2780. (PMID: 28609832)
Br J Cancer. 2019 Jan;120(1):63-68. (PMID: 30377338)
Genome Med. 2019 Jun 20;11(1):39. (PMID: 31221204)
Cancer Res. 2012 Mar 1;72(5):1081-91. (PMID: 22237626)
Eur J Endocrinol. 2018 Feb;178(2):173-180. (PMID: 29187509)
Sci Transl Med. 2014 Apr 2;6(230):230ra45. (PMID: 24695685)
Cancer Immunol Immunother. 2016 Aug;65(8):909-17. (PMID: 27207606)
Endocrinology. 2011 Nov;152(11):4190-8. (PMID: 21862619)
Oncotarget. 2017 Jan 17;8(3):3933-3945. (PMID: 27965469)
J Clin Virol. 2014 Oct;61(2):211-5. (PMID: 25052332)
Cell. 2000 Jan 7;100(1):57-70. (PMID: 10647931)
Cancers (Basel). 2020 Feb 18;12(2):. (PMID: 32085544)
Oncotarget. 2015 Dec 1;6(38):41228-36. (PMID: 26515600)
Cancer Immunol Res. 2019 Jun;7(6):860-865. (PMID: 30996018)
JAMA Oncol. 2019 Aug 22;:. (PMID: 31436791)
Sci Transl Med. 2014 Jan 22;6(220):220ra11. (PMID: 24452263)
Inflamm Bowel Dis. 2009 Jul;15(7):1090-100. (PMID: 19253307)
J Clin Oncol. 2012 Jul 20;30(21):2691-7. (PMID: 22614989)
Nature. 2014 Nov 27;515(7528):558-62. (PMID: 25428503)
N Engl J Med. 2015 Jun 25;372(26):2521-32. (PMID: 25891173)
Tumour Biol. 2016 Sep;37(9):11553-11572. (PMID: 27260630)
Eur J Cancer. 2019 Jan;107:8-14. (PMID: 30529903)
Biopolymers. 2011;96(1):25-31. (PMID: 20560140)
Endocrine. 2020 Jul;69(1):233. (PMID: 30840229)
J Clin Oncol. 2018 Nov 10;36(32):3223-3230. (PMID: 30265610)
J Clin Endocrinol Metab. 2016 Nov;101(11):4431-4439. (PMID: 27571185)
Clin Cancer Res. 2019 Mar 1;25(5):1557-1563. (PMID: 30409824)
Cancer Sci. 2017 May;108(5):1022-1031. (PMID: 28266140)
Ann Oncol. 2017 Oct 1;28(10):2377-2385. (PMID: 28945858)
Cancer Immunol Immunother. 2012 Sep;61(9):1463-72. (PMID: 22318401)
Am J Surg Pathol. 2005 Mar;29(3):329-38. (PMID: 15725801)
Clin Cancer Res. 2012 Dec 15;18(24):6580-7. (PMID: 23087408)
Front Med (Lausanne). 2019 May 29;6:119. (PMID: 31192215)
Blood. 2016 Jun 30;127(26):3321-30. (PMID: 27207799)
Clin Endocrinol (Oxf). 2016 Sep;85(3):331-9. (PMID: 26998595)
J Transl Med. 2009 May 20;7:35. (PMID: 19457253)
J Transl Med. 2011 Nov 28;9:204. (PMID: 22123319)
Neurology. 2017 Sep 12;89(11):1127-1134. (PMID: 28821685)
Nat Med. 2000 May;6(5):583-8. (PMID: 10802717)
Clin Exp Immunol. 2014 May;176(2):266-74. (PMID: 24450998)

Y-sy2018-075 and Y-HR2015-139 Targeted Therapy Fund of Chinese Society of Clinical Oncology; 2020JC-35 Outstanding Youth Project of Shaanxi Province; 320.6750.19094-51 Wu Jieping Medical Foundation

0 (Biomarkers)
0 (Immune Checkpoint Inhibitors)

Date Created: 20201215 Date Completed: 20210906 Latest Revision: 20210906

20240829

PMC7734811

10.1186/s13046-020-01749-x

33317597